Phaseline

Companies › Shenzhen Wingor Biotechnology

Shenzhen Wingor Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
hUC-MSCs treatment (high dose)
Human umbilical cord mesenchymal stem cells
–Phase 2Acute Ischemic Stroke AIS; Premature Ovarian InsufficiencyMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07084012hUC-MSCs treatment (high dose)Phase 2Acute Ischemic Stroke AISNeurologyMay 2027
NCT07084012hUC-MSCs treatment (high dose)Phase 2Acute Ischemic Stroke AISNeurologyMay 2027
NCT07775391hUC-MSCs treatment (high dose)Phase 1Premature Ovarian InsufficiencyMetabolic and endocrineSep 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NeuroBiogen Corxel Pharmaceuticals Urovant Sciences MediciNova PRG Science & Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.